Clinical Trials
41 trialsEVEREST-2
A2 Biotherapeutics Inc.
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
DUAL-MESO-NK
Beijing Biotech
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Short Neoadjuvant Hemithoracic IMRT for MPM
University Health Network, Toronto
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
TYK Medicines, Inc
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
National Cancer Center, China
NECIM
University Hospital, Antwerp
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
MESODEC
University Hospital, Antwerp
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Immuno-MESODEC
University Hospital, Antwerp
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
REGOMUNE
Institut Bergonié
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
ImmVira Pharma Co. Ltd
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
University of Zurich
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
Istituto Clinico Humanitas
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Kissei Pharmaceutical Co., Ltd.
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Oshadi Drug Administration
1716-12
Virttu Biologics Limited
N08CPA
The Netherlands Cancer Institute
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
National Cancer Institute (NCI)
MESO-02
University College, London
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Nevada Cancer Institute